- In July 2023, Quest Diagnostics introduced its first consumer-initiated genetic test using cutting-edge technology to analyze individuals' risk for hereditary health conditions. This move marks a significant step toward personalized healthcare by allowing consumers to access advanced genetic insights directly. It empowers individuals to take proactive health measures without needing a physician referral. The launch strengthens Quest’s position in the esoteric testing space and broadens market accessibility. This initiative is expected to drive higher consumer engagement and expand the demand for direct-to-consumer genetic diagnostics
- In July 2022, Laboratory Corporation of America Holdings (LabCorp) launched its innovative Neurofilament Light Chain (NfL) blood test for detecting markers of neurodegenerative diseases. The test provides clinicians with a non-invasive and efficient tool to identify conditions such as multiple sclerosis and Alzheimer’s at an early stage. By facilitating quicker diagnoses, it helps streamline patient management and treatment planning. This development enhances LabCorp’s neurology-focused offerings within the esoteric testing domain. It also reflects the market’s growing emphasis on specialized, disease-targeted diagnostics
- In May 2022, LabCorp unveiled a novel immunohistochemistry (IHC) test to evaluate Lymphocyte-activation gene 3 (LAG-3) expression in tumor tissue samples. The test supports precision oncology by aiding oncologists in identifying candidates for immunotherapy. It allows for more targeted and effective cancer treatments based on individual tumor biology. This advancement reinforces LabCorp’s commitment to expanding its oncology diagnostics portfolio. It contributes to the growing integration of personalized medicine in esoteric testing
- In February 2021, Quest Diagnostics partnered with GRAIL to support the Galleri multi-cancer early detection blood test. This test uses next-generation sequencing to screen for multiple types of cancer from a single blood sample. The collaboration demonstrates a strong focus on innovation in early cancer detection and diagnosis. By participating in such cutting-edge projects, Quest strengthens its role in advancing esoteric testing technologies. The partnership reflects the market’s shift toward non-invasive, early diagnostic tools with broad clinical applications
- In January 2021, OPKO Health Inc. (BioReference Laboratories) launched Scarlet Health, a fully integrated in-home diagnostic platform in the U.S. The platform enables patients to schedule and receive lab services at home, enhancing convenience and access to care. This digital innovation caters to the growing demand for remote and flexible healthcare solutions. It significantly extends diagnostic services to underserved or mobility-limited populations. Scarlet Health represents a major step in decentralizing esoteric testing and expanding its market reach
